Edgewise Therapeutics, Inc. (EWTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 23, 2022, covers the results of the Annual Meeting of Stockholders held by Edgewise Therapeutics, Inc. on that date. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boulder, Colorado.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The primary event is the completion of the Annual Meeting and the ratification of corporate governance proposals.
Corporate Governance and Voting Results
The stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Class I Directors
- Kenneth Harrison, Ph.D.: Elected with 37,108,884 votes For, 6,977,766 Withheld, and 1,496,573 Broker Non-Votes.
- Alan Russell, Ph.D.: Elected with 36,943,573 votes For, 7,143,077 Withheld, and 1,496,573 Broker Non-Votes.
- Both directors were elected to serve until the 2025 annual meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the appointment of KPMG LLP for the fiscal year ending December 31, 2022.
- Voting results: 45,582,421 For, 614 Against, and 188 Abstain.
Investor Verification Checklist
- Verify the tenure of the newly elected directors (Kenneth Harrison and Alan Russell) through the 2025 annual meeting.
- Confirm KPMG LLP's engagement as the independent auditor for the fiscal year ending December 31, 2022.
- Review the Company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K does not contain financial data.